Editor of Patient Care Online.
Adjusted Donanemab Dosing Lowers ARIA-E Risk in Early Alzheimer Disease: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Lifts Clinical Hold on Novavax’s COVID-19-Influenza Combination Vaccine
The FDA cleared Novavax to start enrolling the planned phase 3 trial after a safety concern was found to be unrelated to the combination vaccine.
Patient Perspectives on Colonoscopies: Daily Dose
November Issue of Patient Care Online Digital Edition is Now Live
Find details on the surge in US pertussis cases, the first self-administered flu vaccine, and study findings underscoring the evolving nature of long COVID.
Respiratory Virus Season 2024-2025: Expert Insights to Help Primary Care Prepare
Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.
Dupilumab Effective for Severe Atopic Dermatitis at 5 Years: Daily Dose
New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity
SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.
FIT Completion Rates Back Screening for CRC at Age 45: Daily Dose
Semaglutide May Reduce Alzheimer’s Risk in Adults with T2D: Daily Dose
ObesityWeek 2024: Viking Therapeutics Presents New Positive Data from VK2735 Obesity Program
Results from the VENTURE phase 2 trial and a phase I oral formulation study found that VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.
Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Soars, According to New Research
Clinicians should continue to monitor trade-offs between pharmacologic and surgical management of obesity, researchers said.
FDA Approves New Treatment for Uncomplicated UTIs: Daily Dose
Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose
Worst States for Health Care in the US: 2024
Get a quick look at the US worst states for health care ranked using a composite score that included measures of cost, access, and outcomes.
GLP-1RAs Reduce the Risk of Early-Onset Colorectal Cancer in Adults with T2D
ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.
Social, Racial Disparities in Flu, COVID-19, RSV Vaccine Uptake: Daily Dose
Modified Donanemab Dosing Reduces ARIA-E in Adults with Early Symptomatic Alzheimer Disease
New phase 3b data suggest that a modified titration of donanemab reduces the risk of brain swelling and fluid accumulation at 24 weeks.
Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose
Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy
Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.
Novel DHE Nasal Spray for Acute Treatment of Migraine: Daily Dose
GLP-1RAs Reduce Suicide Risk in Youth with Obesity: Daily Dose
Survey Reveals Patient Concerns Over Colonoscopy Prep, Barriers to Procedure
More than half of US adults who had a colonoscopy in past 5 years said they wish they knew more information before their first procedure.
Orexo Launches New OX640 Clinical Trial in People with Allergic Rhinitis
The company is advancing development of the intranasal epinephrine medication following positive phase 1 data.
New Drug Boosts COPD Lung Function, QoL Regardless of Severity: Daily Dose
ACIP Recommends 2nd COVID-19 Shot for Older Adults, Immunocompromised Individuals
CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.
Drug Duo Improves COVID-19 Outcomes: Daily Dose
New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024
In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.
COVID-19 Raises Risk of MACE up to 3 Years Later: Daily Dose
Beer, Cider Linked to Higher Risk of Gout: Daily Dose
Similar Rates of FIT Completion Support Initiating CRC Screening at Age 45: New Research
Nearly 40% of adults aged 45 to 50 years completed a fecal immunochemical test within 3 months, according to a large retrospective study.
